• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Editorial: To Beam, or Not to Beam-That Is the Question: Reflecting on the Role of Neoadjuvant Radiotherapy in Resectable Pancreatic Cancer.

作者信息

Ye Linda, Molin Marco Dal, He Jin

机构信息

Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

出版信息

Ann Surg Oncol. 2025 Sep 1. doi: 10.1245/s10434-025-18210-y.

DOI:10.1245/s10434-025-18210-y
PMID:40887571
Abstract
摘要

相似文献

1
Editorial: To Beam, or Not to Beam-That Is the Question: Reflecting on the Role of Neoadjuvant Radiotherapy in Resectable Pancreatic Cancer.社论：放疗，还是不放疗——这是个问题：对新辅助放疗在可切除胰腺癌中作用的思考
Ann Surg Oncol. 2025 Sep 1. doi: 10.1245/s10434-025-18210-y.
2
Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages.胰腺癌的术前/新辅助治疗：反应和切除率的系统评价和荟萃分析。
PLoS Med. 2010 Apr 20;7(4):e1000267. doi: 10.1371/journal.pmed.1000267.
3
Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer.对局部晚期宫颈癌女性患者进行子宫切除术并辅以放疗或化疗或两者联合治疗。
Cochrane Database Syst Rev. 2015 Apr 7(4):CD010260. doi: 10.1002/14651858.CD010260.pub2.
4
Comparison of neoadjuvant treatment and surgery first for resectable or borderline resectable pancreatic carcinoma: A systematic review and network meta-analysis of randomized controlled trials.新辅助治疗与手术优先治疗可切除或交界可切除胰腺癌的比较：一项随机对照试验的系统评价和网络荟萃分析。
PLoS One. 2024 Mar 7;19(3):e0295983. doi: 10.1371/journal.pone.0295983. eCollection 2024.
5
Comparing upfront surgery with neoadjuvant treatments in patients with resectable, borderline resectable or locally advanced pancreatic cancer: a systematic review and network meta-analysis of randomized clinical trials.比较可切除、边界可切除或局部进展期胰腺癌患者的 upfront 手术与新辅助治疗：随机临床试验的系统评价和网络荟萃分析。
Int J Surg. 2024 Jun 1;110(6):3900-3909. doi: 10.1097/JS9.0000000000001313.
6
Neoadjuvant therapy for patients with borderline resectable pancreatic cancer: A systematic review and meta-analysis of response and resection percentages.可切除边缘胰腺癌患者的新辅助治疗：反应率和切除率的系统评价与荟萃分析
Pancreatology. 2016 Jan-Feb;16(1):28-37. doi: 10.1016/j.pan.2015.11.007. Epub 2015 Dec 2.
7
Comparison of the upfront surgery and neoadjuvant therapy in resectable and borderline resectable pancreatic cancer: an updated systematic review and meta-analysis.可切除和交界可切除胰腺癌的 upfront 手术与新辅助治疗比较：一项更新的系统评价和荟萃分析。
Updates Surg. 2024 Jan;76(1):1-15. doi: 10.1007/s13304-023-01626-0. Epub 2023 Aug 28.
8
Neoadjuvant Therapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: A Systemic Review and Meta-Analysis.可切除及边缘可切除胰腺癌的新辅助治疗与直接手术：一项系统评价和荟萃分析
J Surg Res. 2025 Jul;311:221-231. doi: 10.1016/j.jss.2025.04.042. Epub 2025 May 28.
9
Optimizing neoadjuvant chemoradiation in resectable and borderline resectable pancreatic cancer: Evidence-based insights.优化可切除及边界可切除胰腺癌的新辅助放化疗：基于证据的见解
World J Clin Oncol. 2025 Jul 24;16(7):106107. doi: 10.5306/wjco.v16.i7.106107.
10
Diagnostic accuracy of laparoscopy following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer.计算机断层扫描（CT）后腹腔镜检查对评估胰腺癌和壶腹周围癌根治性切除可能性的诊断准确性。
Cochrane Database Syst Rev. 2016 Jul 6;7(7):CD009323. doi: 10.1002/14651858.CD009323.pub3.

本文引用的文献

1
Nonoperative Management of Technically Resectable Pancreatic Cancer With Ablative Radiation Therapy.可技术切除胰腺癌的消融放疗非手术治疗
JAMA Oncol. 2025 Apr 10. doi: 10.1001/jamaoncol.2025.0460.
2
Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.新辅助FOLFIRINOX方案与直接手术治疗可切除胰头癌的比较（NORPACT-1）：一项多中心、随机、2期试验
Lancet Gastroenterol Hepatol. 2024 Mar;9(3):205-217. doi: 10.1016/S2468-1253(23)00405-3. Epub 2024 Jan 15.
3
Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial.
术前 mFOLFIRINOX 对比 mFOLFIRINOX 联合短程放疗治疗边界可切除胰腺腺癌的疗效：A021501 期随机临床试验。
JAMA Oncol. 2022 Sep 1;8(9):1263-1270. doi: 10.1001/jamaoncol.2022.2319.
4
Impact of resection margin status on survival in pancreatic cancer patients after neoadjuvant treatment and pancreatoduodenectomy.新辅助治疗和胰十二指肠切除术后，切缘状态对胰腺癌患者生存的影响。
Surgery. 2020 May;167(5):803-811. doi: 10.1016/j.surg.2019.12.008. Epub 2020 Jan 25.
5
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.FOLFIRINOX 或吉西他滨作为胰腺癌的辅助治疗。
N Engl J Med. 2018 Dec 20;379(25):2395-2406. doi: 10.1056/NEJMoa1809775.
6
Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma.胰腺导管腺癌切除术后复发的模式、时间和预测因素。
Ann Surg. 2018 May;267(5):936-945. doi: 10.1097/SLA.0000000000002234.
7
The use of adjuvant chemotherapy for pancreatic cancer varies widely between hospitals: a nationwide population-based analysis.胰腺癌辅助化疗的使用在不同医院之间差异很大：一项基于全国人口的分析。
Cancer Med. 2016 Oct;5(10):2825-2831. doi: 10.1002/cam4.921. Epub 2016 Sep 27.
8
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.FOLFIRINOX 对比吉西他滨治疗转移性胰腺癌。
N Engl J Med. 2011 May 12;364(19):1817-25. doi: 10.1056/NEJMoa1011923.